Search the Newsreel

Venus Metals (ASX:VMC): Youanmi Royalty Sale Delivers Major Shareholder Return

Janus Living prices 16 million-share follow-on offering at $29 per share

Janus Living has priced a public offering of 16 million shares of Class A-1 common stock at $29 per share, with an option for underwriters to purchase an additional 2.4 million shares. The offering is expected to close on August 12, 2026, and proceeds …

Nu Skin Enterprises, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:NUS) 2026-08-10

Janus Living to Use 16M-Share Offering Proceeds for Acquisitions

Janus Living Announces Pricing of Public Offering of Class A-1 Common Stock

Janus Living, Inc. (NYSE: JAN) has announced the pricing of its public offering of 16,000,000 shares of Class A-1 common stock at $29.00 per share. The company has also granted underwriters a 30-day option to purchase an additional 2,400,000 shares. The proceeds from this …

Nu Skin Enterprises (NYSE:NUS) Releases Quarterly Earnings Results, Meets Expectations

Nu Skin Enterprises (NUS) Releases Q2 2026 Earnings: Revenue Falls and Loss Widens

Nu Skin Enterprises Q2 Adjusted Earnings, Revenue Fall; Lowers 2026 Guidance; Shares Down After-Hours

NuScale Power (NYSE:SMR) Stock Price Down 6.1% - Here's Why

Nu Skin Enterprises (NUS) Matches Q2 Earnings Estimates

Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.2 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was …

Nu Skin Enterprises (NYSE:NUS) Releases Q3 2026 Earnings Guidance

Janus Living Expects New Share Offering to Fund Acquisitions

Nu Skin Enterprises Reports Second Quarter Results

PROVO, Utah, August 10, 2026--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results. Executive Summary Q2 2026 vs. Prior-year Quarter Revenue $320.1 million; (17.1)% (1.0)% FX impact or $(4.0) million Earnings Per Share (EPS) $(5.14) or $0.20 excluding non-cash impairment and …

NuScale Power Stock Barely Budged After Earnings. Time to Buy?

Key Points NuScale Power failed to meet analyst expectations last quarter. But the next major growth catalyst could arrive later this year.10 stocks we like better than NuScale Power › On paper, NuScale Power(NYSE: SMR) failed to meet expectations when it reported quarterly earnings …

VENUSPIPES: Record revenue, strong order book, and margin expansion expected from value-added products

Janus Henderson Group PLC Cuts Stake in Janus International Group, Inc. $JBI

Janus Henderson Group PLC significantly reduced its stake in Janus International Group, Inc. (NYSE:JBI) by 87.0% in the first quarter, selling 2.36 million shares and retaining 354,174 shares. Despite this, other institutional investors increased their holdings, with institutional ownership reaching 88.78%. The company reported …

VENUSPIPES: Q1 FY27 revenue hit an all-time high, with strong growth in value-added solutions and export markets

VENUSPIPES: Revenue and net profit rose year-over-year, with EPS at ₹12.75 for Q1 FY27

Cygnus Metals (ASX:CY5) — Quebec and Western Australia Exploration Activity

Venus Pipes & Tubes posts record ₹320.5 crore revenue in Q1FY27

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

Genus Paper & Boards Ltd Revenue Breakdown – NSE:GENUSPAPER

Janus Living (NYSE:JAN) - Stock Analysis

This Simply Wall St report provides a detailed stock analysis of Janus Living, Inc. (NYSE:JAN), a U.S. publicly traded REIT focused on senior housing. The analysis covers the company's valuation, future growth prospects (forecasted 114.52% annual earnings growth), past performance, financial health, dividends, management, …

Sei Investments Co. Has $2.67 Million Stock Holdings in Janus International Group, Inc. $JBI

Sei Investments Co. significantly increased its stake in Janus International Group, Inc. (NYSE:JBI) by 83.3% in the first quarter, now holding 517,883 shares valued at approximately $2.67 million. Institutional investors collectively own 88.78% of JBI's outstanding stock. Despite missing earnings per share estimates, the …

Nu Skin Enterprises, Inc. $NUS Shares Bought by Dimensional Fund Advisors LP

NuScale Power Q2 Earnings Call Highlights

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - John Hopkins Chief Financial Officer - Robert Hamady Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript …

Agenus (AGEN) Stock Drops As One Off Gain Masks Profit Slip

Price to earnings forward of Oceanus Group Limited – SGX:579

NU SKIN ENTERPRISES Q2 2026 Earnings Preview: Recent $NUS Insider Trading, Hedge Fund Activity, and More

JAN Q2 Earnings Call Highlights

Key Points Interested in JAN? Here are five stocks we like better. Strong second-quarter results: Revenue rose 45% year over year, adjusted EBITDA increased 34%, and adjusted FFO per share grew 40%, supported by organic growth and approximately $800 million of first-half acquisitions. Operational …

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver …

Agenus Inc (AGEN) Stock News Today

This page provides news and analysis for Agenus Inc (AGEN) stock, a company in the Biotechnology & Medical Research sector. It lists the current stock price, market cap, and P/E ratio, alongside links to financial data, ownership, dividends, and discussions. The news section highlights …

AGENUS INC Q2 2026: Revenue $34.5M, EPS $0.96— 10-Q Summary

AGENUS INC reported a strong second quarter for 2026, with revenue reaching $34.5 million, a 34.3% increase year-over-year. The company achieved a net income of $38.6 million for the year-to-date, contrasting sharply with a loss in the prior year, and diluted EPS of $0.96. …

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional …

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.